Skip to content
Menu

Roth Capital Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $55

Benzinga Newsdesk 8 months ago

NewsPrice TargetAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Roth Capital analyst Jonathan Aschoff maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $57 to $55.

Roth Capital analyst Jonathan Aschoff maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $57 to $55.

Read at benzinga.com